UNSPSC 51293206: Pheniprazine hydrochloride

This classification denotes a monoamine oxidase inhibitor with the molecular formula C9H14N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5B3OM8452C, chemically known as hydrazine, (.alpha.-methylphenethyl)-, monohydrochloride but more generally known as pheniprazine hydrochloride, which bears US NIH Compound Identifier 5929. Most nations, for tariff and trade purposes, schedule pheniprazine hydrochloride under HS 29280090 and SITC 51486.

As of Q4 2014, PHENIPRAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pheniprazine hydrochloride bears US NLM identifiers UMLS ID C2347502 and NCI Concept Code C73612. SMILES: CC(CNN)C1CCCCC1.CL.

UNSPSC 51293206 Pheniprazine hydrochloride, a Commodity code, does not align with the state and local procurement activity recently tagged under it. The three most recent opportunities — a Seminole County naloxone and drug deactivation systems purchase, a Texas HHS direct-to-manufacturer prescription program RFI, and a Minnesota multistate cooperative purchasing agreement for generic pharmaceuticals and OTC products — span naloxone distribution, pharmacy benefit program design, and broad pharmaceutical sourcing but do not reference pheniprazine hydrochloride specifically. The code shows little relevant recent activity; the opportunities appear to reflect misclassification or a broader pharmaceutical commodity grouping than the code's name suggests.

State and local buyers tagged under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances serving participating state and local governments (Minnesota Multistate Cooperative Purchasing Alliance, with participation extending to Oregon). Recent solicitations span January through June 2026, with the Seminole County naloxone IFB closing July 26, 2023 (note: posted June 30, 2026 but with an inconsistent due date), the Texas HHS RFI closing April 3, 2026, and the Minnesota MMCAP RFP for generic pharmaceuticals closing March 26, 2026. The geographic spread includes Florida, Texas, and the Upper Midwest, though the Minnesota procurement serves participating jurisdictions across multiple states. Without clear activity specific to pheniprazine hydrochloride, the code does not support a reliable sourcing strategy at this tier.